Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Healthstream (HSTM) Gains from Sales and Divestitures (2017 - 2025)

Historic Gains from Sales and Divestitures for Healthstream (HSTM) over the last 10 years, with Q3 2025 value amounting to $15000.0.

  • Healthstream's Gains from Sales and Divestitures changed N/A to $15000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $15000.0, marking a year-over-year change of. This contributed to the annual value of $175000.0 for FY2024, which is 1006.29% up from last year.
  • Latest data reveals that Healthstream reported Gains from Sales and Divestitures of $15000.0 as of Q3 2025.
  • Over the past 5 years, Healthstream's Gains from Sales and Divestitures peaked at $175000.0 during Q4 2024, and registered a low of $15000.0 during Q3 2025.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $123000.0 (2022), whereas its average is $101857.1.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first skyrocketed by 222.22% in 2021, then surged by 3369.57% in 2022.
  • Quarter analysis of 5 years shows Healthstream's Gains from Sales and Divestitures stood at $92000.0 in 2021, then skyrocketed by 33.7% to $123000.0 in 2022, then grew by 29.27% to $159000.0 in 2023, then grew by 10.06% to $175000.0 in 2024, then tumbled by 91.43% to $15000.0 in 2025.
  • Its Gains from Sales and Divestitures was $15000.0 in Q3 2025, compared to $22000.0 in Q2 2025 and $127000.0 in Q1 2025.